- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hypertrophic cardiomyopathy
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 481KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 81KB)
Mavacamten – November 2023
Mavacamten: Capsule 2.5 mg, Capsule 5 mg, Capsule 10 mg, Capsule 15 mg; Camzyos®
Last updated
1 March 2024